BioSpace News Archive

Alzheon, Inc. announced statistically significant and clinically relevant reduction in plasma biomarkers of neurodegeneration, preservation of brain volume, and positive cognitive effects in Early AD patients who are carriers of apolipoprotein ε4 allele following 24 months of treatment with investigational agent ALZ-801 in the Phase 2 biomarker trial.

Helius Medical Technologies, Inc. today announced that Antonella Favit-Van Pelt, M.D., Ph.D., Helius’ Chief Medical Officer, will present at the Interdisciplinary Association of Neuroscience and Rehabilitation (IAFNR) Conference from September 28 to October 1, 2023.

Sernova Corp. today announced it will host two investor and analyst conference calls, with corresponding live webcasts.

OnPoint Surgical, Inc. today announced that the accuracy of the OnPoint Augmented Reality Spine System has been reported in two separate presentations at the 2023 Congress of Neurological Surgeons, Sept. 9 – 13, in Washington, D.C.

AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease.

Aurora Spine Corporation announced today that it is in full commercial release of its proprietary SiLO TFX™ MIS Sacroiliac Joint Fixation Device system.

Sensei Biotherapeutics, Inc. today announced it will present additional preclinical data on SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Seventh Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, being held September 20 – 23, 2023 in Milan, Italy.

Kyverna Therapeutics today announced that KYV-101 was generally well tolerated with no report of immune effector cell-associated neurotoxicity syndrome (ICANS) after the standard 28-day post infusion observation period of the first U.S. patient enrolled in its Phase 1 clinical trial in subjects with relapsed or refractory lupus nephritis (LN).

Rocket Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a public offering price of $16.00 per share and to certain investors, pre-funded warrants to purchase 3,126,955 shares of common stock at a price of $15.99 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant.

Amphastar Pharmaceuticals, Inc. announced the pricing of $300.0 million aggregate principal amount of 2.00% convertible senior notes due 2029 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.